Purinergic Signaling and the Postmenopausal Heart

Description

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Conditions

Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction

Study Overview

Study Details

Study overview

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

PGC-1, Purines and the Postmenopausal Heart

Purinergic Signaling and the Postmenopausal Heart

Condition
Diastolic Heart Failure
Intervention / Treatment

-

Contacts and Locations

Boston

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients undergoing cardiac surgery under cardiopulmonary bypass.
  • * Refusal to participate
  • * Emergency surgery
  • * Pre-existing heart block
  • * Preexisting atrial fibrillation
  • * Redo surgery
  • * Estrogen or hormone replacement therapy
  • * History of chronic heart failure
  • * History of major kidney disease

Ages Eligible for Study

30 Years to 88 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Beth Israel Deaconess Medical Center,

Robina Matyal, MD, PRINCIPAL_INVESTIGATOR, Beth Israel Deaconess Medical Center, Professor of Anesthesia

Simon Robson, MD, PhD, PRINCIPAL_INVESTIGATOR, Beth Israel Deaconess Medical Center,Vice Chair Research

Study Record Dates

2025-06